Stoke Therapeutics, Inc. (STOK) Income Statement
STOK 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSTOK revenue and net income
Where STOK's revenue goes
2025Each bar shows an amount and its share of revenue. STOK kept −3.7% of revenue as net income.
STOK profit margins
STOK growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +404.5% | +145.9% | — | — |
| Gross profit | +404.5% | +145.9% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
STOK quarterly EPS vs estimates
Stoke Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 3, 2026 (estimate $-0.88).
STOK income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $184.4M | $36.6M | $8.8M | $12.4M | $3.0M | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $4.4M | $4.7M | $3.5M | $2.2M | $1.9M | $450,000 | $214,000 | $113,000 |
| Gross profit | $184.4M | $36.6M | $8.8M | $12.4M | −$2.2M | −$1.9M | −$450,000 | −$214,000 | −$113,000 |
| Research & development | $137.9M | $89.1M | $82.2M | $77.8M | $54.2M | $32.2M | $23.8M | $8.4M | $3.6M |
| Sales, general & admin | $67.1M | $48.8M | $43.6M | $38.9M | $31.9M | $20.8M | $11.9M | $4.4M | $2.0M |
| Total operating expenses | $205.0M | $137.9M | $123.6M | $116.8M | $86.1M | $53.0M | $35.7M | $12.8M | $5.6M |
| Operating income | −$20.6M | −$101.4M | −$114.8M | −$104.4M | −$86.1M | −$53.0M | −$35.7M | −$12.8M | −$5.6M |
| Interest income | — | — | — | — | $120,000 | $744,000 | $3.4M | $270,000 | $0 |
| Interest expense | $9,000 | $12.6M | $9.9M | $3.1M | $120,000 | $0 | $0 | $0 | $0 |
| Income before taxes | −$6.9M | −$89.0M | −$104.7M | −$101.1M | −$85.8M | −$52.2M | −$32.3M | −$12.5M | −$5.6M |
| Income taxes | — | −$89.0M | $4.6M | −$8.0M | −$1.1M | −$1.6M | −$3.8M | $260,000 | $0 |
| Net income | −$6.9M | −$89.0M | −$104.7M | −$93.1M | −$84.7M | −$50.6M | −$28.5M | −$12.5M | −$5.6M |
| EBITDA | −$5.1M | −$86.8M | −$102.2M | −$102.8M | −$85.1M | −$52.2M | −$35.2M | −$12.6M | −$5.4M |
| EPS (diluted) | −$0.12 | −$1.68 | −$2.37 | −$2.60 | −$2.33 | −$1.56 | −$8.78 | −$0.53 | — |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | −74.3% | — | — | — | — |
| Operating margin | −11.2% | −277.3% | −1,307.2% | −841.2% | −2,868.8% | — | — | — | — |
| Net margin | −3.7% | −243.4% | −1,192.5% | −750.6% | −2,823.7% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.3M | $6.2M | $1.4M | $10.6M | $13.8M | $158.6M | $22.6M | $4.9M | $4.8M | $4.2M | $2.8M | $3.3M |
| Cost of revenue | $1.1M | $1.0M | $1.1M | $989,000 | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.2M | $1.2M |
| Gross profit | $8.2M | $5.2M | $347,000 | $9.6M | $13.8M | $158.6M | $22.6M | $4.9M | $3.7M | $3.1M | $1.6M | $2.1M |
| Research & development | $49.0M | $39.7M | $41.3M | $37.3M | $25.9M | $32.7M | $23.4M | $22.2M | $20.6M | $21.8M | $21.2M | $19.6M |
| Sales, general & admin | $25.3M | $20.0M | $21.1M | $16.0M | $15.3M | $14.7M | $12.8M | $12.7M | $13.0M | $10.2M | $10.6M | $10.3M |
| Total operating expenses | $73.6M | $58.6M | $61.8M | $52.7M | $41.1M | $47.3M | $36.3M | $34.9M | $33.1M | $31.5M | $31.2M | $29.3M |
| Operating income | −$65.4M | −$53.4M | −$61.4M | −$43.1M | −$27.3M | $111.2M | −$13.7M | −$30.0M | −$29.3M | −$28.4M | −$29.6M | −$27.2M |
| Interest expense | $17,000 | $23,000 | $3,000 | $3,000 | $3,000 | $1,000 | — | $3.5M | $3.7M | $2.4M | $2.6M | $2.7M |
| Income before taxes | −$61.6M | −$50.0M | −$57.9M | −$39.6M | −$23.5M | $114.2M | −$10.5M | −$26.4M | −$25.7M | −$26.4M | −$27.0M | −$24.5M |
| Income taxes | — | — | — | −$1.3M | — | $1.3M | — | −$1.1M | — | $1.1M | $10.7M | −$3.3M |
| Net income | −$61.6M | −$50.0M | −$57.9M | −$38.3M | −$23.5M | $112.9M | −$10.5M | −$26.4M | −$25.7M | −$26.4M | −$27.0M | −$24.5M |
| EBITDA | −$65.0M | −$46.2M | −$57.5M | −$38.6M | −$23.0M | $114.6M | −$10.0M | −$25.9M | −$25.1M | −$25.8M | −$26.3M | −$23.9M |
| EPS (diluted) | −$0.93 | −$0.79 | −$0.97 | −$0.65 | −$0.40 | $1.90 | −$0.18 | −$0.47 | −$0.46 | −$0.57 | −$0.60 | −$0.55 |
| Gross margin | 87.8% | 83.2% | 24.8% | 90.7% | 100.0% | 100.0% | 100.0% | 100.0% | 77.0% | 73.6% | 56.6% | 63.7% |
| Operating margin | −701.7% | −857.6% | −4,382.2% | −405.3% | −197.6% | 70.2% | −60.4% | −613.1% | −607.4% | −673.0% | −1,055.9% | −823.3% |
| Net margin | −660.8% | −802.7% | −4,132.2% | −360.7% | −170.0% | 71.2% | −46.4% | −540.0% | −531.9% | −625.6% | −962.1% | −741.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in STOK's financial statements (latest annual report filed March 16, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
STOK financial results
In fiscal year 2025 (ended December 31, 2025), Stoke Therapeutics reported revenue of $184.4 million, up 404.5% from the year before. It had a net loss of $6.9 million, a net profit margin of −3.7%. Diluted earnings per share came to −$0.12.
See the STOK stock overview for the latest quote and news, or the STOK chart for price history and technical indicators.
STOK income statement FAQ
What is Stoke Therapeutics's annual revenue?
Stoke Therapeutics reported total revenue of $184.4 million for fiscal year 2025, which ended on December 31, 2025. That was up 404.5% from $36.6 million the previous year.
Is Stoke Therapeutics profitable?
No. Stoke Therapeutics reported a net loss of $6.9 million in fiscal 2025, a net profit margin of −3.7%; its operating margin was −11.2%.
What is Stoke Therapeutics's gross margin?
Stoke Therapeutics's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Stoke Therapeutics kept $100 after the direct cost of its products and services.
How much does Stoke Therapeutics spend on research and development?
Stoke Therapeutics spent $137.9 million on research and development in fiscal 2025, 74.8% of revenue.
What are Stoke Therapeutics's earnings per share?
Stoke Therapeutics earned $-0.12 per diluted share in fiscal 2025, compared with $-1.68 a year earlier.
When will Stoke Therapeutics report its next earnings?
Stoke Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 after the market closes.
When does Stoke Therapeutics's fiscal year end?
Stoke Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 16, 2026.